Drug intelligence / Profile preview

CP

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

"CP" is an abbreviation used in various contexts within the provided clinical trial and publication excerpts. While it frequently refers to medical conditions such as Cerebral Palsy and Chronic Pancreatitis, or medical devices like Impella-CP, it also serves as a code name for specific drug-like substances. In one instance, "CP" denotes "Vitamin C formulation 4, 1000 mg", a comparator product in a pharmacokinetic study. In another, it refers to "convalescent plasma", a biological product containing SARS-CoV-2 antibodies used for passive immunization. Due to these multiple distinct meanings, "CP" is considered a non-specific term. For the purpose of populating specific drug-related fields, this entry primarily focuses on "Vitamin C formulation 4".

Other names: Vitamin C formulation 4, 1000 mgConvalescent Plasma

Beyond the preview

Go deeper on CP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CP.

Explore the full profile